Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

被引:0
作者
Brittany Knick Ragon
Courtney D. DiNardo
机构
[1] The Levine Cancer Institute,Department of Hematologic Oncology and Blood Disorders
[2] Carolinas HealthCare System,Department of Leukemia
[3] The University of Texas MD Anderson Cancer Center,undefined
来源
Current Hematologic Malignancy Reports | 2017年 / 12卷
关键词
IDH1; IDH2; AML; Novel therapeutics; Differentiation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:537 / 546
页数:9
相关论文
共 218 条
[1]  
Yang H(2012)IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives Clin Cancer Res: Off J Am Assoc Cancer Res 18 5562-5571
[2]  
Ye D(2010)Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism JNCI J Natl Cancer Inst 102 932-941
[3]  
Guan K-L(2016)Targeting isocitrate dehydrogenase (IDH) in cancer Discov Med 21 373-380
[4]  
Xiong Y(2012)IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 483 474-478
[5]  
Reitman ZJ(2010)Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene 29 6409-6417
[6]  
Yan H(2010)IDH mutations in glioma and acute myeloid leukemia Trends Mol Med 16 387-397
[7]  
Fujii T(2009)Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739-30
[8]  
Khawaja MR(2011)Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 17-567
[9]  
DiNardo CD(2010)Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 553-2498
[10]  
Atkins JT(2012)Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production Oncogene 31 2491-4652